Y
Y Biologics
Daejeon KRFounded 201280 employees
Private CapbiotechPrivateOncology
Platform: Antibody Discovery
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
4
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Adagratapinarof | YB-9807 | Phase 3 | 3 | SGLT2 | GIST | ||
| YB-6541 | YB-6541 | Phase 3 | 2 | WRN | HNSCC | ||
| Rimarelsin | YB-4678 | Phase 3 | 1 | FLT3 | CRC | ||
| YB-3612 | YB-3612 | Phase 1 | 1 | HER2 | IPFTTR Amyloidosis |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)